VIRUS TODAY: Merck to produce J&J shot, Dems set to debate
Drugmaker Merck & Co. will help produce rival Johnson & Johnson’s newly approved coronavirus vaccine in an effort to expand supply more quickly
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Here's what's happening Tuesday with the coronavirus pandemic in the U.S.:
THREE THINGS TO KNOW TODAY:
— Drugmaker Merck & Co. will help produce rival Johnson & Johnson’s newly approved coronavirus vaccine to try to expand supply more quickly.
— Democrats are sorting through lingering disagreements over emergency jobless benefits and other issues and preparing to commence Senate debate on a $1.9 trillion COVID-19 relief plan.
— A leader of the U.N.-backed project to deploy COVID-19 vaccines to the needy in both rich and poor countries acknowledges the rollout has gone slower than expected in some places because of issues with shipping and approval, but says “ultimately” all doses will be made available.
THE NUMBERS:
CASES: According to data through March 1 from Johns Hopkins University, the seven-day rolling average for daily new cases in the U.S. dropped from 85,813.9 on Feb. 15 to 67,760.3 on Monday.
DEATHS: According to data through March 1 from Johns Hopkins University, the seven-day rolling average for daily new deaths in the U.S. went from 2,361.9 on Feb. 15 to 2,046.1 on Monday.
POSITIVITY RATE: According to data through March 1 from the COVID Tracking Project, the seven-day rolling positivity rate for testing in the U.S. went from 5.6 on Feb. 15 to 4.4 on Monday.
VACCINES: 50.7 million people, or 15.3% of the U.S. population, have received at lease one dose of a coronavirus vaccine, according to the CDC, while 25.5 million people have completed their vaccination, or 7.7% of the population.
QUOTABLE: "It was allowing them to feel like it was OK to admit our sadness in this moment.” — Artist Kristina Libby , who started the Floral Heart Project to give the survivors of COVID-19 victims places to mourn.
ON THE HORIZON: The Caribbean is hunting for visitors and vaccines as it seeks to jump-start the stalled economy of one of the world’s most tourism-dependent regions. Clear waters and warm sand had attracted a record 31.5 million tourists to the region in 2019. But visits plummeted by an estimated 60% to 80% last year. Local governments are turning to India and China for vaccines to make it safe to welcome back tourists without prompting a spike in COVID-19 cases that could overwhelm their fragile health care systems.
___
Find AP’s full coverage of the coronavirus pandemic at https://apnews.com/hub/coronavirus-pandemic